Country: South Africa
Language: English
Source: South African Health Products Regulatory Authority (SAHPRA)
Lennon
INDICATIONS [/za_1342.html#1] [/za_1342.html#1] [/za_1342.html#1] CONTRA-INDICATIONS [/za_1342.html#1] [/za_1342.html#1] DOSAGE [/za_1342.html#1] [/za_1342.html#1] SIDE-EFFECTS [/za_1342.html#1] [/za_1342.html#1] [/za_1342.html#1] PREGNANCY [/za_1342.html#1] [/za_1342.html#1] OVERDOSE [/za_1342.html#1] IDENTIFICATION [/za_1342.html#1] [/za_1342.html#1] PATIENT INFORMATION IPRADOL INJECTION 5 ΜG/2 ML - DISCONTINUED SCHEDULING STATUS: IPRADOL INJECTION 5 µg/2 mL S4 PROPRIETARY NAME (and dosage form): IPRADOL INJECTION 5 ΜG/2 ML - DISCONTINUED COMPOSITION: Each ampoule of 2 mL contains 5 micrograms HEXOPRENALINE sulphate. PHARMACOLOGICAL CLASSIFICATION A 10.2 Bronchodilators. PHARMACOLOGICAL ACTION IPRADOL exhibits a long acting bronchospasmolytic effect. In therapeutic doses, heart rate and blood pressure are only slightly affected. IPRADOL eliminates functional bronchostenosis by the relaxation of bronchial spasm and in long term treatment IPRADOL causes a decrease of pathological hypersecretory changes of the bronchial mucosa. IPRADOL provokes an improved ventilation of the alveoli, a decrease of obstructive reversible pulmonary emphysema and thus a decrease of respiratory action, which finally normalises the respiratory gas values and the blood count. INDICATIONS IPRADOL is a stimulant of the beta receptors in the bronchi and thus a bronchodilator. IPRADOL is effective for the relief of bronchospasm caused by allergic asthma, acute, sub-acute and chronic bronchitis and emphysema. CONTRA-INDICATIONS Hypersensitivity to any of the ingredients. Safety in pregnancy and lactation has not been established. IPRADOL should be used with great care in patients with cardiovascular disease such as ischeamic heart disease, arrhythmia or tachycardia, occlusive v Read the complete document